Advice
following a full submission
rivaroxaban (Xarelto®) is not recommended for use within NHS Scotland.
Indication under review: rivaroxaban co-administered with aspirin alone or with aspirin plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.
Rivaroxaban in addition to standard care significantly reduced the occurrence of the primary composite endpoint: death from cardiovascular causes, myocardial infarction, or stroke, compared to standard care alone.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice197KB (PDF)
Medicine details
- Medicine name:
- rivaroxaban (Xarelto)
- SMC ID:
- 1062/15
- Indication:
- Rivaroxaban co-administered with aspirin alone or with aspirin plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.
- Pharmaceutical company
- Bayer plc/Bayer Schering Pharma
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 13 July 2015